Physician profile
Marlyn Generillo
NPI 1386870673
$6,871.36
in general payments reported to CMS, 2019-2025
37 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $921 · 2021: $2,310 · 2022: $512 · 2023: $841 · 2024: $924 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,246 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,246.23 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,229.69 | 2021 | |
| Novo Nordisk INC | $951.64 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $716.61 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $464.24 | 2020-2025 | Jardiance, Zepbound, Emgality |
| Abbvie INC. | $376.93 | 2021-2025 | |
| Pfizer INC. | $315.23 | 2020-2025 | |
| Glaxosmithkline, LLC. | $214.86 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $212.37 | 2022-2024 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $205.80 | 2020-2025 | Repatha, Otezla, Krystexxa |
| Eisai INC. | $187.16 | 2019-2021 | |
| Antares Pharma, INC. | $184.64 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Currax Pharmaceuticals LLC | $160.38 | 2021-2024 | Contrave, Onzetra Xsail, Nexletol |
| Exact Sciences Corporation | $156.40 | 2023-2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $142.28 | 2020-2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.99 | 2019-2024 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlyn Generillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.